Literature DB >> 28642279

Role of MyD88 signaling in the imiquimod-induced mouse model of psoriasis: focus on innate myeloid cells.

Sara Costa1, Olivia Marini1, Dalila Bevilacqua1, Anthony L DeFranco2, Baidong Hou3, Silvia Lonardi4, William Vermi4, Pamela Rodegher5, Anna Panato5, Franco Tagliaro5, Clifford A Lowell6, Marco A Cassatella1, Giampiero Girolomoni7, Patrizia Scapini8.   

Abstract

Psoriasis is a chronic skin disease associated with deregulated activation of immune cells and keratinocytes. In this study, we used the imiquimod (IMQ)-induced mouse model of psoriasis to dissect better the contribution of hematopoietic and skin-resident stromal cells to psoriasis development. The comparison of disease development in mice carrying the hematopoietic cell-specific deletion of MyD88 (Myd88fl/flVav-cre+ mice) with mice carrying the total MyD88 deficiency (Myd88-/- mice), we show that the progression of skin and systemic inflammation, as well as of epidermal thickening, was completely dependent on MyD88 expression in hematopoietic cells. However, both Myd88-/- mouse strains developed some degree of epidermal thickening during the initial stages of IMQ-induced psoriasis, even in the absence of hematopoietic cell activation and infiltration into the skin, suggesting a contribution of MyD88-independent mechanisms in skin-resident stromal cells. With the use of conditional knockout mouse strains lacking MyD88 in distinct lineages of myeloid cells (Myd88fl/flLysM-cre+ and Myd88fl/flMRP8-cre+ mice), we report that MyD88 signaling in monocytes and Mϕ, but not in neutrophils, plays an important role in disease propagation and exacerbation by modulating their ability to sustain γδ T cell effector functions via IL-1β and IL-23 production. Overall, these findings add new insights into the specific contribution of skin-resident stromal vs. hematopoietic cells to disease initiation and progression in the IMQ-induced mouse model of psoriasis and uncover a potential novel pathogenic role for monocytes/Mϕ to psoriasis development. © Society for Leukocyte Biology.

Entities:  

Keywords:  monocytes/macrophages; neutrophils; skin inflammation

Mesh:

Substances:

Year:  2017        PMID: 28642279      PMCID: PMC6608051          DOI: 10.1189/jlb.3MA0217-054RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  Topical Application of a Dual ABC Transporter Substrate and NF-κB Inhibitor Blocks Multiple Sources of Cutaneous Inflammation in Mouse Skin.

Authors:  Luowei Li; Christophe Cataisson; Brittany Flowers; Elise Fraser; Vanesa Sanchez; Chi-Ping Day; Stuart H Yuspa
Journal:  J Invest Dermatol       Date:  2019-01-23       Impact factor: 8.551

2.  IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis.

Authors:  Charlie Bridgewood; Gareth W Fearnley; Anna Berekmeri; Philip Laws; Tom Macleod; Sreenivasan Ponnambalam; Martin Stacey; Anne Graham; Miriam Wittmann
Journal:  Front Immunol       Date:  2018-02-26       Impact factor: 7.561

Review 3.  Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences.

Authors:  Wolf-Henning Boehncke
Journal:  Front Immunol       Date:  2018-04-05       Impact factor: 7.561

4.  A requirement for slc15a4 in imiquimod-induced systemic inflammation and psoriasiform inflammation in mice.

Authors:  Alexis D Griffith; Asifa K Zaidi; Ashley Pietro; Matthew Hadiono; Jessica S Yang; Rachel Davis; Daniel L Popkin
Journal:  Sci Rep       Date:  2018-09-27       Impact factor: 4.379

5.  IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis.

Authors:  Jérémie D Goldstein; Esen Y Bassoy; Assunta Caruso; Jennifer Palomo; Emiliana Rodriguez; Sylvain Lemeille; Cem Gabay
Journal:  Life Sci Alliance       Date:  2020-04-28

6.  IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment.

Authors:  Laura Mercurio; Martina Morelli; Claudia Scarponi; Elan Z Eisenmesser; Nunzianna Doti; Gianluca Pagnanelli; Emanuela Gubinelli; Cinzia Mazzanti; Andrea Cavani; Menotti Ruvo; Charles A Dinarello; Cristina Albanesi; Stefania Madonna
Journal:  Cell Death Dis       Date:  2018-10-30       Impact factor: 8.469

7.  Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis.

Authors:  Lucas S Shores; Sean H Kelly; Kelly M Hainline; Jutamas Suwanpradid; Amanda S MacLeod; Joel H Collier
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.